CD274 and neoplasm: However, ICBs using anti-CTLA-4 (NCT01473940, NCT02527434, NCT02558894, NCT02879318) and anti-PD-1/PD-L1 (NCT01876511, NCT03214250, NCT02866383, NCT02323191, NCT03637491) in clinical trials did not show efficacy in pancreatic cancer due to the immunosuppressive tumor microenvironment of PAAD and multiple factors inducing resistance [18,19,20].